Loading clinical trials...
Loading clinical trials...
An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Conditions
Interventions
RO7795081
Placebo
Locations
2
China
Nanjing Gulou Hospital
Nanjing, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China
Start Date
March 30, 2026
Primary Completion Date
December 29, 2026
Completion Date
December 29, 2026
Last Updated
April 13, 2026
NCT00104325
NCT01399385
NCT06857942
NCT03807401
NCT05774834
NCT07310264
Reference Study ID Number: YP46260 https://forpatients.roche.com/
CONTACT
888-662-6728 (U.S. Only)global-roche-genentech-trials@gene.comLead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions